Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.
about
Inquilinus limosus in patients with cystic fibrosis, GermanyThe multifarious, multireplicon Burkholderia cepacia complexCulture enriched molecular profiling of the cystic fibrosis airway microbiomeMulticenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic FibrosisPulmonary exacerbations in cystic fibrosis with negative bacterial cultures.Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosisLow rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients.Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices.Management of refractory Pseudomonas aeruginosa infection in cystic fibrosisPlasma TGF-β₁ in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy.Whole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France.Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy.A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic FibrosisOutcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis.Molecular identification of Pseudomonas aeruginosa recovered from cystic fibrosis patients.Fourier transform infrared spectroscopy for rapid identification of nonfermenting gram-negative bacteria isolated from sputum samples from cystic fibrosis patientsEvolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.Identification of new bacterial and fungal pathogens on surveillance bronchoscopy prior to sinus surgery in patients with cystic fibrosis.Proteomics of hosts and pathogens in cystic fibrosis.In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.Superiority of molecular techniques for identification of gram-negative, oxidase-positive rods, including morphologically nontypical Pseudomonas aeruginosa, from patients with cystic fibrosis.Novel pan-genomic analysis approach in target selection for multiplex PCR identification and detection of Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholderia cepacia complex species: a proof-of-concept study.In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.Infection prevention and control guideline for cystic fibrosis: 2013 update.Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex.Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
P2860
Q24620282-524B3383-D12F-4AD2-8580-DE8F6627B262Q28301994-B5DB8161-C950-4EDB-BD2A-3DB8DE0AC798Q28742049-904646CC-B4E3-418C-A7D5-BC9902069E19Q33783497-FBE19102-C91D-48CC-A896-97A902EC1230Q34118967-E961E433-8065-4ED9-A84D-CF04CFC9E025Q34568983-D9460CF7-26F6-476C-BAA6-70BD74DBAAB4Q34956792-07F37717-0719-4EAB-A392-64078F0E3C29Q34998656-BB0CF10F-C624-4B0C-8AA7-3508F443BA0AQ35026630-3DECB722-4E5D-42C9-8F1A-EE585EC65723Q35046565-71755044-D2EB-441F-84F9-40FE745AC8DAQ35076797-A2B43305-59E8-4008-8779-BA52BA0CF906Q35124580-7F3C3C66-16FC-423C-AE4C-439049A0DD88Q35855673-4F197A73-303F-435E-A89C-AE33A094EB32Q36009637-E4A22119-CD84-470B-98B6-8F60F3AF7523Q36478351-5B92FE10-1040-4089-A779-3A29C9AE7028Q36845344-54336A36-DC82-4876-AA9C-53FC4173DE01Q36895659-6C399A4B-CF15-4C4B-BA4B-8A6F909400DBQ36980425-167A0FD3-9BAB-441B-885F-89CF621E049DQ38204951-43A980C7-B2ED-44D5-93B2-AFFAD67290ADQ38270707-D7CE39DB-9AA0-4A20-95D0-551F4BF47C81Q39659034-863000F5-3EB1-4267-B63C-577051ED3BFAQ40164055-68FB84F0-CB40-45B6-ADB3-DB6B23DC5606Q41819863-FAA581B2-AF79-4F30-A4E1-C2D363476FEFQ41916977-43E673D1-479C-49F0-A4CB-22A497FDD5D2Q42017846-16C3C068-3912-432C-BD83-0893169245F5Q42206103-A4CD368F-4663-4F6B-A131-270CB56C57B1Q42576819-34878A72-DDEA-4DF5-85D3-947D64E44D5AQ44834295-2E7CEA05-ECE7-4723-9B3D-BC29C29A8A6AQ53750484-1603240C-E732-43CD-A339-13C0326678DE
P2860
Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Laboratory aspects of manageme ...... patients with cystic fibrosis.
@ast
Laboratory aspects of manageme ...... patients with cystic fibrosis.
@en
type
label
Laboratory aspects of manageme ...... patients with cystic fibrosis.
@ast
Laboratory aspects of manageme ...... patients with cystic fibrosis.
@en
prefLabel
Laboratory aspects of manageme ...... patients with cystic fibrosis.
@ast
Laboratory aspects of manageme ...... patients with cystic fibrosis.
@en
P2860
P1476
Laboratory aspects of manageme ...... patients with cystic fibrosis.
@en
P2093
Melissa B Miller
Peter H Gilligan
P2860
P304
P356
10.1128/JCM.41.9.4009-4015.2003
P407
P577
2003-09-01T00:00:00Z